Back to Search
Start Over
Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO-incompatible kidney transplantation and the associated risk factors.
- Source :
-
International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2019 Dec; Vol. 26 (12), pp. 1128-1137. Date of Electronic Publication: 2019 Oct 06. - Publication Year :
- 2019
-
Abstract
- Objectives: To analyze the prevalence of systemic de novo thrombotic microangiopathy in ABO-incompatible kidney transplantation and risk factors associated with this condition.<br />Methods: A total of 201 patients who received living-donor kidney transplantation (114 patients with ABO-identical kidney transplantation and 87 patients with ABO-incompatible kidney transplantation) were retrospectively analyzed. Systemic de novo thrombotic microangiopathy was diagnosed clinically according to the presence of thrombocytopenia with microangiopathic hemolytic anemia and pathological findings of thrombotic microangiopathy. Anti-A and anti-B antibodies were purified from human plasma, and these antibodies' bindings to human kidney were investigated in vitro.<br />Results: ABO-incompatible kidney transplantation was a significant risk factor of systemic de novo thrombotic microangiopathy (odds ratio 55.9, 95% CI 1.8-8.9, P < 0.001) after transplantation. Multivariate logistic regression analysis showed that non-use of mycophenolate mofetil, pretreatment immunoglobulin G antibody titer ≥64-fold and pretransplant immunoglobulin M antibody titer ≥16-fold were significant risk factors for systemic de novo thrombotic microangiopathy in ABO-incompatible kidney transplantation. Microvascular inflammation of 1-h post-transplant biopsy could be observed more frequently in thrombotic microangiopathy patients than in non-thrombotic microangiopathy patients. Anti-A and anti-B antibodies purified from human plasma showed a strong in vitro reaction against human kidney when the antibody titer was ≥16-fold.<br />Conclusions: Antibody titer should be decreased to ≤16-fold until the day of ABO-incompatible kidney transplantation by desensitization therapy including mycophenolate mofetil. The 1-h biopsy results might help to diagnose systemic de novo thrombotic microangiopathy.<br /> (© 2019 The Japanese Urological Association.)
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Allografts
Biopsy
Blood Group Incompatibility blood
Blood Group Incompatibility drug therapy
Blood Group Incompatibility immunology
Child
Female
Graft Rejection blood
Graft Rejection immunology
Graft Rejection prevention & control
Graft Survival immunology
Hemagglutinins blood
Hemagglutinins immunology
Humans
Immunoglobulin G blood
Immunoglobulin G immunology
Immunoglobulin M blood
Immunoglobulin M immunology
Kidney
Living Donors
Male
Middle Aged
Prevalence
Retrospective Studies
Risk Factors
Thrombotic Microangiopathies blood
Thrombotic Microangiopathies immunology
Thrombotic Microangiopathies prevention & control
Transplantation Conditioning methods
Young Adult
ABO Blood-Group System
Blood Group Incompatibility complications
Graft Rejection epidemiology
Immunosuppressive Agents therapeutic use
Kidney Transplantation adverse effects
Thrombotic Microangiopathies epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1442-2042
- Volume :
- 26
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- International journal of urology : official journal of the Japanese Urological Association
- Publication Type :
- Academic Journal
- Accession number :
- 31587389
- Full Text :
- https://doi.org/10.1111/iju.14118